dalteparin has been researched along with Sicca Syndrome in 1 studies
Dalteparin: A low-molecular-weight fragment of heparin, prepared by nitrous acid depolymerization of porcine mucosal heparin. The mean molecular weight is 4000-6000 daltons. It is used therapeutically as an antithrombotic agent. (From Merck Index, 11th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cardoso, R | 1 |
| Gonçalo, M | 1 |
| Tellechea, O | 1 |
| Maia, R | 1 |
| Borges, C | 1 |
| Silva, JA | 1 |
| Figueiredo, A | 1 |
1 other study available for dalteparin and Sicca Syndrome
| Article | Year |
|---|---|
Livedoid vasculopathy and hypercoagulability in a patient with primary Sjögren's syndrome.
Topics: Adult; Anticoagulants; Diagnosis, Differential; Enoxaparin; Female; Humans; Injections, Subcutaneous | 2007 |